证券代码：002370 证券简称：亚太药业 公告编号：2024-077 债券代码：128062 债券简称：亚药转债 浙江亚太药业股份有限公司（以下简称"公司"或"亚太药业"） 于 2024 年 3 月 28 日召开的第七届董事会第二十四次会议审议通过 了《关于清算注销合资公司的议案》，同意清算注销合资公司 YATAI & BBT Biotech Ltd.（以下简称"合资公司"），并授权公司管理层按照 法定程序办理清算、注销等相关事宜具体情况，2024 年 6 月 28 日， 公司开户银行中国银行股份有限公司柯桥支行收到合资公司分配给 股东亚太药业的剩余财产分配款 2,766,105.25 加元，具体内容详见 2024 年 3 月 30 日、2024 年 7 月 2 日公司在指定信息披露媒体《证券 时报》和巨潮资讯网（www.cninfo.com.cn）上刊载的《关于清算注销 合资公司的公告》、《关于合资公司清算注销进展公告》。 截至本公告披露日，合资公司 YATAI & BBT Biotech Ltd.已完 成注销手续，并收到绍兴市商务局出具的《企业境外投资注销确认函》， 合资公司分配给股东亚太药业的剩余财产 ...

Financial Performance - The company's revenue for Q3 2024 was ¥84,902,518, representing a 5.18% increase year-over-year, while year-to-date revenue reached ¥306,835,789, up 1.65% compared to the same period last year[3]. - The net profit attributable to shareholders for Q3 2024 was a loss of ¥8,934,704.33, a 51.72% increase in loss compared to the same period last year, with a year-to-date loss of ¥3,459,530.47, reflecting a significant increase of 374.48%[3]. - Total operating revenue for Q3 2024 reached ¥306,835,789.08, an increase from ¥301,858,122.44 in Q3 2023, reflecting a growth of approximately 1.6%[17]. - Operating profit for Q3 2024 was reported at -¥3,202,585.73, an improvement compared to -¥49,291,975.33 in the same period last year[18]. - Net profit for Q3 2024 was -¥3,459,530.47, compared to a net profit of ¥1,260,384.91 in Q3 2023, indicating a significant decline[18]. - The total comprehensive income attributable to the parent company's shareholders was -2,861,149.28 CNY, down from 1,260,384.91 CNY year-on-year[19]. - The basic and diluted earnings per share for Q3 2024 were both -0.0056 CNY, compared to 0.0023 CNY in the previous year[19]. Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥35,870,275.86, showing a substantial increase of 244.54% compared to the same period last year[10]. - Cash flow from operating activities generated a net inflow of 35,870,275.86 CNY, a significant improvement from a net outflow of -24,816,449.96 CNY in the same period last year[21]. - Cash inflow from sales of goods and services was 193,325,869.73 CNY, compared to 172,369,477.49 CNY in the previous year[20]. - Total cash outflow from operating activities was 171,108,464.35 CNY, down from 211,912,748.33 CNY year-on-year[21]. - The net cash flow from investing activities was -5,107,308.62 CNY, compared to a positive inflow of 2,876,915.08 CNY in the previous year[22]. - The net cash flow from financing activities was -61,901,761.80 CNY, compared to -16,004,922.79 CNY in the same period last year[22]. - The ending balance of cash and cash equivalents was 689,103,730.30 CNY, down from 704,487,317.43 CNY at the end of the previous year[22]. Assets and Liabilities - Total assets at the end of Q3 2024 were ¥1,358,023,867.27, a decrease of 4.99% from the previous year-end, while equity attributable to shareholders increased by 7.67% to ¥625,426,532.05[4]. - The company's total assets as of Q3 2024 were ¥1,358,023,867.27, down from ¥1,429,373,407.82 in Q3 2023, a decrease of about 5%[16]. - Total liabilities decreased to ¥732,597,335.22 from ¥848,498,998.29, reflecting a decline of approximately 13.6%[16]. - The company's equity attributable to shareholders increased to ¥625,426,532.05 from ¥580,874,409.53, an increase of about 7.6%[16]. Investments and Expenses - Research and development expenses decreased by 35.51% to ¥10,253,111.79 compared to the previous year, indicating a reduction in investment in this area[8]. - The company reported a significant increase in investment income of 665.18%, amounting to ¥15,853,845.06, primarily due to the distribution of remaining assets from a joint venture[8]. - Total operating costs decreased to ¥327,680,456.45 from ¥353,686,573.69, marking a reduction of about 7.4% year-over-year[17]. - Research and development expenses decreased to ¥10,253,111.79 from ¥15,897,936.95, a reduction of approximately 35.5%[18]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 64,255[11]. - The largest shareholder, Ningbo Fubon Holdings, holds 14.30% of shares, totaling 89,420,000 shares[11]. - The top ten shareholders include significant stakes from domestic non-state-owned enterprises[11]. - The report indicates no changes in the participation of major shareholders in margin financing and securities lending activities[12]. Other Notable Events - The company completed the transfer of 100% equity of Shanghai New Summit Biopharmaceutical Co., Ltd. for a nominal price of ¥1, while waiving debts of ¥1,456,800[13]. - The company is currently undergoing a capital reduction process following the equity transfer[13]. - The company received government subsidies amounting to ¥1,413,188.10 during the reporting period, contributing to its financial performance[5]. - The company experienced a 100% reduction in short-term borrowings, totaling ¥0.00, as a result of repaying bank loans[7]. - The company reported a 70.16% decrease in contract liabilities, reflecting a reduction in advance payments received[7]. - The company's cash and cash equivalents as of September 30, 2024, amount to ¥689,103,730.30, a decrease from ¥720,474,524.86 at the beginning of the period[14]. - Accounts receivable increased to ¥80,215,026.89 from ¥79,510,294.14[14]. - The company's prepayments decreased to ¥2,014,727.90 from ¥4,244,178.55[14]. - The company's receivables financing decreased to ¥19,738,669.93 from ¥32,288,532.83[14]. - The company has not undergone an audit for the Q3 2024 report[23].

证券代码：002370 证券简称：亚太药业 公告编号：2024-075 债券代码：128062 债券简称：亚药转债 浙江亚太药业股份有限公司 本公司及董事会全体成员保证公告内容真实、准确和完整，不 存在虚假记载、误导性陈述或者重大遗漏。 特别提示 股票代码：002370 股票简称：亚太药业 债券代码：128062 债券简称：亚药转债 初始转股价格为 16.30 元/股，最新转股价格为 3.00 元/股 转股日期：2019 年 10 月 9 日至 2025 年 4 月 2 日 根据《深圳证券交易所股票上市规则》、《深圳证券交易所可转换 公司债券业务实施细则》等有关规定，浙江亚太药业股份有限公司（以 下简称"亚太药业"或"公司"）现将 2024 年第三季度可转换公司债 券（以下简称"可转债"）转股及公司股份变动情况公告如下： 一、可转债发行上市概况 经中国证券监督管理委员会《关于核准浙江亚太药业股份有限公 司公开发行可转换公司债券的批复》（证监许可〔2019〕225 号）核准， 公司于 2019 年 4 月 2 日公开发行了 965 万张可转换公司债券，每张 面值 100 元，发行总额 9.65 亿元。 - 1 ...

证券代码：002370 证券简称：亚太药业 公告编号：2024-074 债券代码：128062 债券简称：亚药转债 浙江亚太药业股份有限公司 关于诉讼事项的进展公告 本公司及董事会全体成员保证公告内容真实、准确和完整，不 存在虚假记载、误导性陈述或者重大遗漏。 浙江亚太药业股份有限公司（以下简称"公司"或"亚太药业"） 于近日收到浙江省高级人民法院下发的《传票》（（2024）浙民申3471 号），浙江省高级人民法院受理的浙商银行股份有限公司绍兴越城支 行诉公司的股东损害债权人利益责任纠纷案件将于2024年9月13日进 行询问，现将有关情况公告如下： 一、诉讼的基本情况 因浙江亚太集团有限公司、绍兴柯桥亚太房地产有限公司、绍兴 柯桥中国轻纺城港越路纺织品市场有限公司、陈尧根、钟婉珍与浙商 银行股份有限公司绍兴越城支行金融借款合同纠纷，浙商银行股份有 限公司绍兴越城支行以股东损害债权人利益责任纠纷为由对公司原 实际控制人陈尧根先生及公司提起诉讼，原告认为陈尧根拒不履行出 资义务，且利用自己是公司实际控制人的强势地位，将本应属于被执 行人浙江亚太集团有限公司的实物出资转移给公司，致使本案原告的 债权无法得到清偿，严 ...

证券代码：002370 证券简称：亚太药业 公告编号：2024-073 债券代码：128062 债券简称：亚药转债 浙江亚太药业股份有限公司 关于出售全资子公司 100%股权暨债务豁免的公告 一、本次交易概述 2024 年 9 月 9 日，公司与宁波和依文化传媒有限公司（以下简 称"和依文化"）签署了《关于上海新高峰生物医药有限公司之股权 转让协议》，将公司持有的上海新高峰生物医药有限公司（以下简称 "上海新高峰"）100%股权转让给和依文化。由于上海新高峰目前净 资产为负，故本次股权转让价格为人民币 1 元。 截至 2024 年 9 月 9 日，上海新高峰应付公司借款为人民币 1,456,800 元，经公司判断该款项全部收回的可能性较低，为顺利实 现本次股权转让交易，同意豁免上海新高峰对公司的债务人民币 1,456,800 元，即交易完成后，上海新高峰不再对公司负有前述债务。 本次债务豁免与股权转让为一揽子交易。 2024 年 9 月 9 日，公司召开了第七届董事会第三十一次会议， - 1 - 会议以 9 票同意，0 票反对，0 票弃权，审议通过了《关于出售全资 子公司 100%股权暨债务豁免的议案》，公司 ...

证券代码：002370 证券简称：亚太药业 公告编号：2024-072 债券代码：128062 债券简称：亚药转债 关于第七届董事会第三十一次会议决议的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、董事会会议通知的时间和方式 浙江亚太药业股份有限公司（以下简称"公司"）第七届董事会 第三十一次会议（以下简称"会议"）通知于 2024 年 9 月 4 日以专人 送达、微信等方式送达各位董事。 2、召开董事会会议的时间、地点和方式 会议于 2024 年 9 月 9 日以通讯表决方式召开。 3、董事会会议出席情况 浙江亚太药业股份有限公司 （一）以 9 票同意，0 票反对，0 票弃权，审议通过了《关于出 售全资子公司 100%股权暨债务豁免的议案》 具体内容详见 2024 年 9 月 10 日公司在指定信息披露媒体《证券 时报》和巨潮资讯网（www.cninfo.com.cn）上刊载的《关于出售全资 1 子公司 100%股权暨债务豁免的公告》。 特此公告。 浙江亚太药业股份有限公司 董 事 会 本次会议的应表决董事 9 人，实际参 ...

阿替洛尔片主要用于治疗高血压、心绞痛、心肌梗死，也可用于 心律失常、甲状腺机能亢进、嗜铬细胞瘤。 二、受理通知书主要内容 证券代码：002370 证券简称：亚太药业 公告编号：2024-071 债券代码：128062 债券简称：亚药转债 浙江亚太药业股份有限公司 关于收到阿替洛尔片一致性评价受理通知书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 浙江亚太药业股份有限公司（以下简称"公司"）于近日收到国 家药品监督管理局下发的关于阿替洛尔片一致性评价的受理通知书。 现将相关情况公告如下： 一、产品相关情况 阿替洛尔片被国家药品监督管理局受理，标志着该品种一致性评 价工作进入了审评阶段，公司将积极推进后续相关工作，如顺利通过 一致性评价将增加其市场竞争力。药品一致性评价审评工作流程有一 定的时间周期，存在不确定性因素，敬请广大投资者审慎决策，注意 投资风险。 特此公告。 浙江亚太药业股份有限公司 产品名称：阿替洛尔片 受理号：CYHB2450466 申请事项：境内生产药品一致性评价申请：国家药品监管部门审 批的补充申请事项；1.已上市化学药品药学变更相关 ...

一、药品基本信息 证券代码：002370 证券简称：亚太药业 公告编号：2024-070 债券代码：128062 债券简称：亚药转债 药品名称：注射用盐酸地尔硫䓬 浙江亚太药业股份有限公司 关于公司注射用盐酸地尔硫䓬首家通过仿制药一致 性评价的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 浙江亚太药业股份有限公司（以下简称"公司"或"亚太药业"） 于近日收到国家药品监督管理局核准签发的关于注射用盐酸地尔硫 䓬的《药品补充申请批准通知书》，公司注射用盐酸地尔硫䓬首家通 过仿制药质量和疗效一致性评价，现将相关情况公告如下： 二、药品的其他相关情况 注射用盐酸地尔硫䓬适用于阵发性室上性心动过速、心房颤动或 心房扑动；用于将阵发性室上性心动过速快速转化为窦性节律；用于 暂时性控制心房颤动或心房扑动过程中过快的心室率；手术时异常高 血压的急救处置；高血压急症；不稳定心绞痛。 剂型：注射剂 规格：10mg 原药品批准文号：国药准字 H20063737 注册分类：化学药品 上市许可持有人：浙江亚太药业股份有限公司 生产企业：浙江亚太药业股份有限公司 审批结论：根据《 ...

Financial Performance - The company reported a significant increase in revenue for the first half of 2024, reaching RMB 1.2 billion, representing a year-on-year growth of 15%[8]. - The company has set a future outlook with a revenue target of RMB 2.5 billion for the full year 2024, which would represent a growth of 10% from 2023[8]. - The company's operating revenue for the reporting period was ¥221,933,271.08, representing a 0.36% increase compared to the same period last year[13]. - Net profit attributable to shareholders decreased by 72.30% to ¥5,475,173.86 from ¥19,766,522.01 in the previous year[13]. - The company reported a net loss of CNY 7,826,660.51 after excluding non-recurring gains and losses, a reduction in loss of 76.86% compared to the previous year[22]. - The company achieved operating revenue of CNY 221,933,271.08, a year-on-year increase of 0.36%[22]. - The company reported a net profit of 997,197.63 yuan from its subsidiary Shaoxing Yatai Pharmaceutical Co., Ltd., contributing significantly to overall performance[41]. - The company reported a total comprehensive income of CNY 6,073,555.05 for the first half of 2024[115]. - The company reported a net profit distribution of 100.00 yuan for the current period, indicating a focus on maintaining profitability[125]. Market Expansion and Product Development - User data indicates a growing customer base, with an increase of 20% in active users compared to the same period last year[8]. - New product development includes the launch of three innovative drugs, with expected market entry by Q4 2024[8]. - The company is expanding its market presence by entering two new provinces, aiming for a 5% market share in these regions by the end of 2025[8]. - The company plans to continue its strategy of "combining imitation and innovation" to enhance drug research and development efforts[18]. - The company is focusing on the development of key generic drugs and their consistency evaluation, with ongoing registration and clinical research projects[22]. - The company plans to continue focusing on market expansion and new product development to enhance future growth prospects[114]. Financial Management and Investments - A strategic acquisition of a local biotech firm was completed, enhancing the company's R&D capabilities and expected to contribute an additional RMB 300 million in revenue annually[8]. - The company has invested RMB 100 million in new technology for production efficiency, projected to reduce costs by 8% over the next year[8]. - The company invested CNY 3,981,353.93 during the reporting period, an increase of 87.31% compared to CNY 2,125,586.24 in the same period last year[34]. - The total amount of funds raised through convertible bonds was CNY 965 million, with a net amount of CNY 952.59 million after deducting fees[34]. - The company has cumulatively used CNY 31,539.63 million of the raised funds, with a remaining balance of CNY 63,759.59 million as of the end of the reporting period[34]. Compliance and Risk Management - The management highlighted the importance of compliance with industry regulations, particularly in drug procurement, to mitigate potential risks[3]. - The company is exposed to risks from industry regulations and policy changes, which could adversely affect operations if not managed properly[42]. - The company is also at risk from centralized procurement policies that may lead to significant changes in drug bidding and pricing, potentially compressing profit margins[43]. - The company acknowledges the risks of new drug development, including potential delays and failures due to various factors[44]. - The company emphasizes the importance of continuous improvement in management and quality control to adapt to new policies and reduce operational risks[42]. Environmental and Quality Control - The report emphasizes the ongoing commitment to quality control and environmental safety in all production processes[3]. - The company is committed to increasing investment in environmental protection to ensure compliance with stricter regulations[44]. - The company has established a quality control system in compliance with GMP standards, but acknowledges the ongoing risk of product quality issues[43]. - The company has established an emergency response plan for environmental incidents and conducts regular inspections to ensure compliance[51]. - The company’s wastewater quality meets the Class III standards of the "Comprehensive Wastewater Discharge Standards" (GB8978-1996) and ammonia nitrogen limits as per the indirect discharge limits[50]. Shareholder and Corporate Governance - The company emphasizes the protection of shareholder and creditor rights through a robust corporate governance structure and timely information disclosure[55]. - The company has implemented a comprehensive human resources management system to safeguard employee rights and promote talent development[56]. - The company has no changes in the use of raised funds during the reporting period[38]. - The company has not reported any major asset or equity sales during the reporting period[39]. - The company has not conducted any repurchase transactions during the reporting period[88]. Legal and Regulatory Matters - The company is involved in multiple lawsuits related to securities false statements, with a total amount involved of 3.8375 million yuan[65]. - The company has recognized an estimated liability of 29.9248 million yuan due to the withdrawal or termination of lawsuits by investors[65]. - The company is actively seeking to enforce the compensation agreement, with ongoing litigation regarding the performance compensation commitment[61]. - The company has taken measures to ensure compliance with performance commitments from the acquisition, including legal actions against the responsible parties[61]. - The company faced a fine of RMB 95,000 for using unregistered special equipment, which was later inspected and approved by the Shaoxing Special Equipment Testing Institute[69]. Financial Reporting and Accounting Policies - The financial statements comply with the accounting standards and accurately reflect the company's financial position as of June 30, 2024[136]. - The company uses the historical cost basis for accounting measurement, except for certain financial instruments[135]. - The company has established specific accounting policies and estimates for financial instrument impairment, fixed asset depreciation, and revenue recognition[135]. - The company recognizes revenue when the company fulfills performance obligations, with sales of chemical drugs recognized at the point of control transfer upon delivery and customer confirmation[187]. - The company recognizes deferred tax assets and liabilities based on temporary differences between the carrying amount of assets and liabilities and their tax bases, using the balance sheet liability method[189].

证券代码：002370 证券简称：亚太药业 公告编号：2024-069 债券代码：128062 债券简称：亚药转债 浙江亚太药业股份有限公司 关于2024年半年度募集资金存放与使用情况的 专项报告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 浙江亚太药业股份有限公司（以下简称"本公司"或"公司"）董事会根据 《深圳证券交易所股票上市规则》《深圳证券交易所上市公司自律监管指引第 1 号—主板上市公司规范运作》《上市公司监管指引第 2 号——上市公司募集资金 管理和使用的监管要求》和《浙江亚太药业股份有限公司募集资金管理制度》的 相关规定，现将本公司 2024 年半年度募集资金存放与使用情况报告如下： 一、募集资金基本情况 1、实际募集资金金额和资金到账时间 经中国证券监督管理委员会证监许可〔2019〕225 号文核准，并经深圳证券 交易所同意，公司于 2019 年 4 月 2 日向社会公众公开发行面值总额 965,000,000.00 元可转换公司债券，期限 6 年。本次发行的可转换公司债券募 集资金总额为 965,000,000.00 元，扣除承销及保荐费 ...